Condition: Diabetes Mellitus, Type 2 · Sponsor: Amgen
Interested? Contact the study team ↓
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria for Part A and B * Participant must be 18-65 years of age * Participant must be overtly healthy Inclusion Criteria for Part C * Participant must be 40-75 years of age * Confirmed diagnoses of T2DM Exclusion Criteria for Part A and B * History of hypotension, syncope, or orthostatic intolerance * Systolic blood pressure \>140 millimeters of mercury (mmHg) or diastolic blood pressure \>90 mmHg Exclusion Criteria for Part C * Hemoglobin A1c (HbA1c) \>10% within the last 3 months * History of hypotension, syncope, or orthostatic intolerance * Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Orange County Research Center | Lake Forest, California, United States | Recruiting |
| Translational Clinical Research LLC | Aventura, Florida, United States | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.